The Anti-Dysenteric Drug Fraxetin Enhances Anti- Tumor E cacy of Gemcitabine and Suppresses Pancreatic Cancer Development by Antagonizing STAT3 Activation

[1]  T. Hofmann,et al.  Pancreatic Ductal Adenocarcinoma (PDAC) Organoids: The Shining Light at the End of the Tunnel for Drug Response Prediction and Personalized Medicine , 2020, Cancers.

[2]  Xinguo Zhu,et al.  Glucose Transporter-1 Cooperating with AKT Signaling Promote Gastric Cancer Progression , 2020, Cancer management and research.

[3]  Hongwei Wang,et al.  IL-37/ STAT3/ HIF-1α negative feedback signaling drives gemcitabine resistance in pancreatic cancer , 2020, Theranostics.

[4]  L. Bouchier-Hayes,et al.  Targeting apoptotic caspases in cancer. , 2020, Biochimica et biophysica acta. Molecular cell research.

[5]  M. Dimopoulos,et al.  JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancer. , 2020, European journal of cancer.

[6]  Dan Yang,et al.  Chemical Constituents from Fraxinus hupehensis and Their Antifungal and Herbicidal Activities , 2020, Biomolecules.

[7]  Yongheng Bai,et al.  Resveratrol suppresses the myofibroblastic phenotype and fibrosis formation in kidneys via proliferation‐related signalling pathways , 2019, British journal of pharmacology.

[8]  B. Parker,et al.  JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression , 2019, Cancers.

[9]  Xiaowu Xu,et al.  FGFBP1, a downstream target of the FBW7/c-Myc axis, promotes cell proliferation and migration in pancreatic cancer. , 2019, American journal of cancer research.

[10]  E. Oldfield,et al.  Farnesyl Pyrophosphate Synthase as a Target for Drug Development: Discovery of Natural Product-Derived Inhibitors and Their Activity in Pancreatic Cancer Cells. , 2019, Journal of medicinal chemistry.

[11]  Jun-feng Wang,et al.  Long non-coding RNA RP11-468E2.5 curtails colorectal cancer cell proliferation and stimulates apoptosis via the JAK/STAT signaling pathway by targeting STAT5 and STAT6 , 2019, Journal of Experimental & Clinical Cancer Research.

[12]  F. Shi,et al.  Colivelin Rescues Ischemic Neuron and Axons Involving JAK/STAT3 Signaling Pathway , 2019, Neuroscience.

[13]  Yan Deng,et al.  Fraxetin Suppresses Proliferation of Non-Small-Cell Lung Cancer Cells via Preventing Activation of Signal Transducer and Activator of Transcription 3. , 2019, The Tohoku journal of experimental medicine.

[14]  D. Tuveson,et al.  IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma. , 2018, Cancer discovery.

[15]  G. Ichim,et al.  Caspase-8 function, and phosphorylation, in cell migration. , 2018, Seminars in cell & developmental biology.

[16]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[17]  W. El-Rifai,et al.  Exposure of Barrett’s and esophageal adenocarcinoma cells to Bile acids activates EGFR-STAT3 signaling axis via induction of APE1 , 2018, Oncogene.

[18]  Mengtao Zhou,et al.  Tyrphostin B42 attenuates trichostatin A-mediated resistance in pancreatic cancer cells by antagonizing IL-6/JAK2/STAT3 signaling. , 2018, Oncology reports.

[19]  H. Y. Kim,et al.  Combined use of CEMIP and CA 19-9 enhances diagnostic accuracy for pancreatic cancer , 2018, Scientific Reports.

[20]  Wei Shen,et al.  Genistein induced anticancer effects on pancreatic cancer cell lines involves mitochondrial apoptosis, G0/G1cell cycle arrest and regulation of STAT3 signalling pathway. , 2018, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[21]  Haitao Zhu,et al.  Combination of gemcitabine and erlotinib inhibits recurrent pancreatic cancer growth in mice via the JAK-STAT pathway , 2018, Oncology reports.

[22]  Guodong Liu,et al.  Effect of fraxetin on proliferation and apoptosis in breast cancer cells , 2017, Oncology letters.

[23]  Xia Wang,et al.  PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database , 2017, Nucleic Acids Res..

[24]  Y. Hsu,et al.  OSU-A9 inhibits pancreatic cancer cell lines by modulating p38-JAK-STAT3 signaling , 2017, Oncotarget.

[25]  Chen Huang,et al.  Regulation of EMT by STAT3 in gastrointestinal cancer (Review). , 2017, International journal of oncology.

[26]  K. Xie,et al.  ESE3 Inhibits Pancreatic Cancer Metastasis by Upregulating E-Cadherin. , 2017, Cancer research.

[27]  Bicheng Chen,et al.  Sonic hedgehog-mediated epithelial-mesenchymal transition in renal tubulointerstitial fibrosis. , 2016, International journal of molecular medicine.

[28]  S. Alahari,et al.  Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications , 2016, Molecular Cancer.

[29]  R. Holcombe,et al.  Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer , 2016, Clinical Cancer Research.

[30]  Qi Zhang,et al.  Inhibition of protein phosphatase 2A sensitizes pancreatic cancer to chemotherapy by increasing drug perfusion via HIF-1α-VEGF mediated angiogenesis. , 2014, Cancer letters.

[31]  A. Alavi,et al.  A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma , 2013, Clinical Cancer Research.

[32]  P. Singh,et al.  Graviola: a novel promising natural-derived drug that inhibits tumorigenicity and metastasis of pancreatic cancer cells in vitro and in vivo through altering cell metabolism. , 2012, Cancer letters.

[33]  N. Merchant,et al.  Src-mediated regulation of E-cadherin and EMT in pancreatic cancer. , 2012, Frontiers in bioscience.

[34]  M. Kanda,et al.  Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. , 2012, Gastroenterology.

[35]  J. Bromberg,et al.  Targeting the interleukin-6/Jak/stat pathway in human malignancies. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  D. Levy,et al.  STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. , 2011, Cancer research.

[37]  A. Scarpa,et al.  Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  I. Cuthill,et al.  Reporting : The ARRIVE Guidelines for Reporting Animal Research , 2010 .

[39]  Guang Yang,et al.  Effects of IL-6 and AG490 on regulation of Stat3 signaling pathway and invasion of human pancreatic cancer cells in vitro , 2010, Journal of experimental & clinical cancer research : CR.

[40]  J. Shea,et al.  Phenotype and Genotype of Pancreatic Cancer Cell Lines , 2010, Pancreas.

[41]  Pui-Kai Li,et al.  Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. , 2010, Cancer research.

[42]  J. Benedí,et al.  Fraxetin prevents rotenone-induced apoptosis by induction of endogenous glutathione in human neuroblastoma cells , 2005, Neuroscience Research.

[43]  Yu Zhao,et al.  Molecular Carcinogenesis , 2020 .

[44]  H. Zhan,et al.  Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion. , 2019, Cancer letters.

[45]  E. Diamandis,et al.  Pancreatic cancer. , 2013, Clinical chemistry.

[46]  B. Kos-Kudła,et al.  The value of the Ki-67 proliferation marker as a prognostic factor in gastroenteropancreatic neuroendocrine tumours. , 2012, Endokrynologia Polska.